Riskpilot← Back to searchSign inGet full accessKrotek Oy
OYActiveY-tunnus 2223120-5Salmintie 4-BWholesale of pharmaceutical and medical goods · NACE 4646Est. 20081 employees
Revenue 2025
EUR 1,2M
-9% vs 2024
EBITDA margin
43.9%
-11% vs 2024
Equity ratio
72.4%
Financial strength
Net profit 2025
EUR 439K
-7% vs 2024
| Revenue | EUR 1,2M | -9% |
| EBITDA | EUR 538K | -11% |
| Net profit | EUR 439K | -7% |
| Total assets | EUR 4,5M | +22% |
| Equity | EUR 3,2M | +10% |
| Employees | 1 | — |
Legal name
Krotek Oy
Y-tunnus number
2223120-5
Legal form
Osakeyhtiö
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
2. lokakuuta 2008
Share capital
EUR 2 500
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2025-01-31
Financial year
January – December
Company purpose
Yhtiön toimiala on laboratoriotarvikkeiden, -reagenssien ja -laitteiden sekä laboratorioiden ATK-järjestelmien maahantuonti ja myynti sekä ISO 9001-palvelu. Yhtiö voi toimintaansa varten omistaa ja hallita kiinteää omaisuutta.
Address
Salmintie 4-B
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 282 | 1 297 | 1 297 | 1 353 | 1 226 |
| Staff expenses | −37 | −37 | −37 | −34 | −47 |
| EBITDA | 470 | 542 | 542 | 605 | 538 |
| Depreciation & amort. | — | −55 | −55 | −29 | −4 |
| EBIT | 470 | 487 | 487 | 576 | 534 |
| Net financials | 47 | 13 | 13 | 17 | 16 |
| Profit before tax | 517 | 499 | 499 | 593 | 549 |
| Tax | 96 | 98 | 98 | 94 | 110 |
| Net profit | 422 | 402 | 402 | 474 | 439 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 2 700 | 2 883 | 3 401 | 3 647 | 4 462 |
| Equity | 2 133 | 2 388 | 2 712 | 2 939 | 3 229 |
| Long-term debt | 12 | 15 | 16 | 15 | 371 |
| Short-term debt | 555 | 480 | 0 | 692 | 863 |
| Total debt | 567 | 496 | 689 | 708 | 1 233 |
EBITDA margin
43.9%
This company
15.8%
Market median
+178% vs market
20212025
Equity ratio
72.4%
This company
38.2%
Market median
+90% vs market
20212025
Return on equity
13.6%
This company
18.4%
Market median
+26% vs market
20212025
Net profit margin
35.8%
This company
8.1%
Market median
+342% vs market
20212025
Asset turnover
0.27×
This company
1.12×
Market median
-76% vs market
20212025
Debt / equity
0.38×
This company
0.62×
Market median
+39% vs market
20212025
- Annual report 2025Filed via PRH / YTJ · Period 2024-02-01 – 2025-01-31
- Annual report 2024Filed via PRH / YTJ · Period 2023-02-01 – 2024-01-31
- Annual report 2023Filed via PRH / YTJ · Period 2022-02-01 – 2023-01-31
- Annual report 2022Filed via PRH / YTJ · Period 2021-02-01 – 2022-01-31
- Annual report 2021Filed via PRH / YTJ · Period 2020-02-01 – 2021-01-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
TM Chief Executive Officer | Chief Executive Officer | 2008 |
MJ Deputy Member | Deputy Member | 2008 |
No data on file.
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Krotek Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Tero Mikael Reijonen | Chief Executive Officer | 0 companies |
| Minna Johanna Reijonen | Deputy Member | 0 companies |